Fig. 3: Different phenotypes of CD8+ and CCT T cells between responders and non-responders were predictive of the clinical efficacy of anti-PD-1 therapy. | Nature Communications

Fig. 3: Different phenotypes of CD8+ and CCT T cells between responders and non-responders were predictive of the clinical efficacy of anti-PD-1 therapy.

From: Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Fig. 3

a, b Longitudinally the levels of Granzyme B and Tbet were consistently higher in responder CD8+ and CCT T cells. Data in longitudinal analysis are presented as mean values +/− SD. c A higher tumor burden was associated with higher frequencies of CD8+CD27+ T cells and CCT T cells. The length of the black arrows corresponds to the tumor size, with the precise value denoted by the black number. The percentages for each subpopulation are based on overall live CD45+ singlet cell counts. R responder, NR non-responder.

Back to article page